

To: (10)(2e) [(10)(2e) @nive.nl]; (10)(2e) [(10)(2e) @rivm.nl]; (10)(2e) [(10)(2e) @rivm.nl]; (10)(2e) [(10)(2e) @rivm.nl];
 (10)(2e) [(10)(2e) @rcsi.ie]; (10)(2e) [(10)(2e) @nive.nl]

From: (10)(2e)

Sent: Wed 9/30/2020 8:00:08 AM

Subject: RE: draft one pager on COVID 19

Received: Wed 9/30/2020 8:01:01 AM

Thanks (10)(2e)

In case it's of interest here's a brief EURACTIV news piece from this morning entitled, 'EU official: Member states' reports on COVID-19 still insufficient': <https://www.euractiv.com/section/coronavirus/news/eu-official-member-states-reports-on-covid-19-still-insufficient/>

It mentions this [ECDC Risk assessment on COVID-19](https://www.ecdc.europa.eu/en/current-risk-assessment-novel-coronavirus-situation) which was released on 24 September 2020: <https://www.ecdc.europa.eu/en/current-risk-assessment-novel-coronavirus-situation>

Best wishes

(10)(2e)

(10)(2e) 0)(2e)
(10)(2e)



Office of Research and Innovation
 (10)(2e) Floor Ardilaun House Block B
 111 St. Stephen's Green D2 Ireland
 T: 01 (10)(2e)
 E: (10)(2e) @rcsi.ie W: www.rcsi.com

Transforming Healthcare Education, Research and Service: RCSI Strategic Plan 2018-2022



If you receive this email outside of your normal working hours, you are not expected to respond until you return to work.

Registered Charity Number: 20001957

From: (10)(2e) <(10)(2e)@nivel.nl>
Sent: Wednesday, September 30, 2020 8:27 AM
To: (10)(2e) <(10)(2e)@rcsi.ie>; (10)(2e)@rivm.nl <(10)(2e)@rivm.nl>; (10)(2e) <(10)(2e)@rivm.nl>; (10)(2e) <(10)(2e)@rivm.nl>; (10)(2e) <(10)(2e)@rcsi.ie>; (10)(2e) <(10)(2e)@nivel.nl>
Subject: RE: draft one pager on COVID 19

Dear all,

Yesterday the one-pager was finalised and approved by the hierarchy at both SANTE and RTD. I am adding it under confidentiality as it cannot be shared with external parties.

In general, I think we provided quite a nice starting point, as it is clearly drafted based on our version, but of course, it was changed and shortened a bit, in part for political considerations, I'm sure. E.g. all references to (10)(2e) plans on eg (10)(2a) have now been kept vague. They also removed the reference to long term disabilities at the start, and the extra questions we added at the closing section, regarding social support for social distancing and vaccination. Also the closing questions on how to further support the MS was removed. One new paragraph I'm copying below, in case it's also interesting for you to know.

Thanks again for your contributions, and assuming (10)(2e) (or a replacement) can join the meeting next Friday, we'll let you know what the outcome was.

Best wishes,

(10)(2e)

◆ The key action of the ERAvsCorona Action Plan is to strengthen the EU response to COVID-19 in the years to come by setting up EU-wide clinical trial networks (notably EU-RESPONSE which builds on the DisCoVeRy trial originally initiated in (10)(2a) in coordination with the (10)(2a). The SUPPORT-E on convalescent plasma to treat COVID-19 will coordinate planning and implementation of large-scale clinical trials across the EU.

(10)(2a)